Koyfin Home > Directory > Health Care > Adverum Biotechnlgs > Preferred Equity

Adverum Biotechnlgs Preferred Equity Chart (ADVM)

Adverum Biotechnlgs annual/quarterly Preferred Equity from 2013 to 2014.
  • Adverum Biotechnlgs Preferred Equity for the quarter ending June 06, 2014 was $60m
  • Adverum Biotechnlgs Preferred Equity for the last 12 months ending June 06, 2014 was $60m
  • Adverum Biotechnlgs Annual Preferred Equity for 2013 was $8m a 68.98% increase of 6m from 2012
  • Adverum Biotechnlgs Annual Preferred Equity for 2012 was $3m
Other Balance Sheet Metrics:
  • Adverum Biotechnlgs Total Assets for the quarter ending September 09, 2018 was $226m a 10.62% increase of 24m year over year
  • Adverum Biotechnlgs Other Liabilities for the quarter ending December 12, 2018 was $2m a -14.42% decrease of 0m year over year
  • Adverum Biotechnlgs Total Equity for the quarter ending September 09, 2018 was $216m a 14.63% increase of 32m year over year
View Chart On Koyfin

Quarterly ADVM Preferred Equity Data

06/2014$60m
12/2013$8m
03/2013$3m

Annual ADVM Preferred Equity Data

2013$8m
2012$3m